Related by context. All words. (Click for frequent words.) 81 metastatic renal cell carcinoma 74 Doxil ® 74 recurrent glioblastoma multiforme 74 metastatic GIST 73 chlorambucil 73 metastatic RCC 73 HER2 positive metastatic breast 73 relapsed MM 73 sorafenib Nexavar 73 temsirolimus 73 assessing T DM1 73 metastatic colorectal cancer 72 carboplatin paclitaxel 72 dasatinib Sprycel ® 72 metastatic CRC 72 mCRC patients 72 Fludara 72 leukemia AML 72 leukemia CLL 72 FOLFIRI 72 relapsed refractory multiple myeloma 72 HRPC 72 dacarbazine 72 Flu Cy 72 recurrent GBM 71 metastatic malignant melanoma 71 gastrointestinal stromal tumor GIST 71 nilotinib 71 ribavirin therapy 71 stage IIIB 71 metastatic renal cell 71 docetaxel chemotherapy 71 Amrubicin 71 metastatic malignant 71 CHOP chemotherapy 71 Aflibercept 71 imatinib Gleevec ® 71 oblimersen 71 pegylated interferon alpha 71 vandetanib 71 refractory NSCLC 71 advanced NSCLC 71 ribavirin RBV 71 mCRC 71 cabazitaxel 71 B CLL 71 pegylated liposomal doxorubicin 71 FOLFOX6 71 erlotinib Tarceva ® 71 EGFR TKI 71 heavily pretreated 71 Torisel 70 prostate cancer CRPC 70 PREZISTA r 70 HBeAg negative 70 recurrent NSCLC 70 receptor tyrosine kinase inhibitor 70 Irinotecan 70 Fludarabine 70 PEG interferon 70 VELCADE melphalan 70 trastuzumab Herceptin ® 70 cetuximab Erbitux R 70 Pemetrexed 70 mycophenolate mofetil 70 metastatic hormone refractory 70 castrate resistant prostate cancer 70 metastatic castration resistant 70 BARACLUDE ® 70 decitabine 70 invasive candidiasis 70 alfa 2a 70 platinum refractory 70 Cloretazine 70 lopinavir r 70 Taxotere ® 70 gefitinib Iressa 70 unresectable 70 Bevacizumab 70 castration resistant prostate cancer 70 Nexavar sorafenib 70 prostate cancer HRPC 70 sunitinib 70 achieved CCyR 70 azacitidine 70 GW# [003] 70 cetuximab Erbitux ® 70 pegylated interferon alfa 2a 70 metastatic HRPC 70 hormone refractory prostate cancer 70 biliary tract cancer 70 Dasatinib 70 mapatumumab 69 metastatic gastric 69 plus dexamethasone 69 alkylating agent 69 plus prednisone 69 bevacizumab Avastin ® 69 PEG IFN 69 lamivudine refractory patients 69 tumors GIST 69 chemoradiotherapy 69 daunorubicin 69 mTOR inhibitor 69 IV NSCLC 69 TroVax ® 69 fluoropyrimidine 69 axitinib 69 MAGE A3 ASCI 69 IRESSA 69 phase IIb clinical 69 galiximab 69 castrate resistant 69 CR nPR 69 multiple myeloma MM 69 TORISEL 69 SCCHN 69 HBeAg positive patients 69 viral kinetics 69 pomalidomide 69 trabectedin 69 KRAS mutant tumors 69 unresectable stage 69 CIMZIA TM 69 ara C 69 Lenalidomide 69 fallopian tube carcinoma 69 antiangiogenic therapy 69 standard chemotherapy regimen 69 micafungin 69 lumiliximab 69 adriamycin 69 operable breast cancer 69 gemcitabine carboplatin 69 HER2 negative 69 Telintra 69 relapsed ovarian cancer 69 follicular NHL 69 Erlotinib 69 non squamous NSCLC 69 low dose cytarabine 69 sunitinib Sutent 69 relapsed refractory 69 dasatinib 69 superficial bladder cancer 69 ACTEMRA TM 69 FOLFOX4 69 gemcitabine Gemzar 69 IFN α 69 FOLFOX 69 goserelin 69 gastrointestinal stromal tumors GIST 68 Follicular Lymphoma 68 prospectively defined 68 KRAS wild 68 invasive aspergillosis 68 Trastuzumab 68 adalimumab Humira 68 ritonavir boosted 68 PegIFN 68 herpetic keratitis 68 5-FU/LV 68 BRIM2 68 Pharmacokinetics PK 68 bevacizumab Avastin 68 SPRYCEL ® 68 docetaxel Taxotere ® 68 idarubicin 68 VIDAZA 68 achieved ACR# 68 CLL SLL 68 cell lymphoma CTCL 68 Peg IFN 68 forodesine 68 EFAPROXYN 68 imatinib therapy 68 virologic response 68 HBeAg negative patients 68 hepatocellular cancer 68 MabCampath 68 pancreatic adenocarcinoma 68 anthracycline taxane 68 relapsing remitting MS RRMS 68 cancer mCRC 68 nucleoside analog 68 FOLFIRI alone 68 cilengitide 68 oral ridaforolimus 68 regorafenib 68 Tarceva TM 68 TEMODAL 68 cisplatin chemotherapy 68 locoregional 68 Gleevec imatinib 68 Ceflatonin 68 taxane chemotherapy 68 resectable 68 pertuzumab 68 free survival PFS 68 basiliximab 68 lymphoma CTCL 68 CANCIDAS 68 Temsirolimus 68 vinorelbine 68 adult chronic ITP 68 estramustine 68 Copegus ribavirin 68 protease inhibitor PI 68 comparator arm 68 AVASTIN 68 Golimumab 68 5-fluorouracil/leucovorin 68 bendamustine 68 Navelbine ® 68 adecatumumab 68 lymphocytosis 68 refractory multiple myeloma 68 neoadjuvant chemotherapy 68 trastuzumab Herceptin R 68 virologic failure 68 relapsed AML 68 liposomal amphotericin B 68 XELOX 68 tocilizumab 68 sunitinib malate 68 ZACTIMA 68 posaconazole 68 EGFR tyrosine kinase inhibitors 68 elacytarabine 68 HuMax CD4 68 CIMZIA ™ 68 refractory acute myeloid 68 relapsed multiple myeloma 68 docetaxel Taxotere 68 monotherapy 68 elotuzumab 68 Peginterferon 68 Cytoxan 68 CTAP# Capsules 68 KRAS mutations occur 68 Alocrest 68 lupus nephritis 68 dacarbazine DTIC 68 cisplatin gemcitabine 68 taxane resistant 68 BAY #-# 68 stage IIIb IV 68 Cloretazine ® 68 ELACYT 68 Fludara ® 67 HCV RESPOND 2 67 unresectable locally advanced 67 ovarian carcinoma 67 myelodysplastic myeloproliferative diseases 67 APTIVUS 67 Gleevec resistant 67 Neoadjuvant 67 peginterferon alfa 2a 67 metastatic colorectal 67 alvespimycin 67 Peginterferon alfa 2b 67 pancreatic carcinoma 67 Velcade bortezomib 67 tyrosine kinase inhibitor 67 grade cervical intraepithelial 67 Aplidin 67 imatinib Gleevec 67 interferon alfa 67 biologic therapy 67 PegIntron 67 placebo dexamethasone 67 noninferiority 67 Traficet EN 67 Metastatic Colorectal Cancer 67 baminercept 67 CYT# potent vascular disrupting 67 tigecycline 67 chronic HBV 67 EGFR expressing mCRC 67 glufosfamide 67 amrubicin 67 heavily pretreated patients 67 SUTENT 67 sorafenib tablets 67 ACZ# 67 Aptivus ® 67 Hepatocellular Carcinoma HCC 67 HBeAg positive 67 interferon alfa 2a 67 gemcitabine chemotherapy 67 PEGINTRON TM 67 metastatic CRPC 67 prostate cancer mCRPC 67 pegylated interferon alfa 2b 67 NSCLC 67 refractory CTCL 67 inhibitor RG# 67 dasatinib Sprycel 67 DAPT 67 DOXIL 67 pain palliation 67 BEACOPP 67 refractory AML 67 MYLOTARG 67 HBeAg seroconversion 67 APTIVUS r 67 Pegylated Interferon 67 thalidomide Thalomid 67 trastuzumab 67 genotypic resistance 67 indolent NHL 67 Degarelix 67 MGd 67 ixabepilone 67 chemoradiation therapy 67 cediranib 67 KRAS status 67 PEGylated Fab fragment 67 pancreatic NET 67 Bezielle 67 oropharyngeal candidiasis OPC 67 gemcitabine 67 malignant pleural mesothelioma 67 irinotecan chemotherapy 67 refractory metastatic colorectal cancer 67 virus HCV protease inhibitor 67 untreated multiple myeloma 67 unfractionated heparin UFH 67 FASLODEX 67 situ CIS 67 gefitinib 67 prostate cancer AIPC 67 YONDELIS 67 tanespimycin 67 liposomal doxorubicin 67 vidofludimus 67 Noxafil 67 Proxinium TM 67 GvHD 67 prostate carcinoma 67 docetaxel prednisone 67 tumor lysis syndrome 67 amoxicillin clavulanate 67 liposomal formulation 67 adalimumab 67 chronic lymphocytic leukemia CLL 67 nonmetastatic 67 advanced unresectable 67 mitomycin 67 abacavir lamivudine 67 IV melanoma 67 cytotoxic therapy 67 gemcitabine Gemzar ® 67 5 fluorouracil leucovorin 67 interferon ribavirin 67 Clolar ® 67 Xanafide 67 Vectibix 67 registrational trial 67 Castration Resistant Prostate Cancer 67 median PFS 67 follicular lymphoma FL 67 paclitaxel carboplatin 67 NMIBC 67 immunomodulatory therapy 67 cytoreductive nephrectomy 67 OncoVEX GM CSF 67 recurrent glioblastoma 66 rituximab refractory 66 sustained virological response 66 remission induction 66 voriconazole 66 Genasense ® 66 Cutaneous T 66 intravesical 66 prostate cancer CaP 66 T#I [002] 66 smoldering multiple myeloma 66 metastatic carcinoma 66 adefovir dipivoxil 66 anthracycline containing 66 sipuleucel T 66 Vidaza azacitidine 66 metaglidasen 66 Nexavar tablets 66 postoperative chemotherapy 66 FUSILEV enhances 66 metastatic colorectal carcinoma 66 clodronate 66 Sprycel dasatinib 66 colorectal liver metastases 66 peginterferon 66 Bortezomib 66 RRMS patients 66 glatiramer acetate 66 #mg BID [001] 66 Paraplatin ® 66 riociguat 66 panitumumab Vectibix 66 plus gemcitabine 66 evaluating tivozanib 66 Hodgkin lymphoma NHL 66 TNF antagonist 66 pegfilgrastim 66 refractory chronic lymphocytic 66 cytotoxic chemotherapy 66 mCRPC 66 bevacizumab Avastin R 66 interferon alfa 2b 66 docetaxel Taxotere R 66 demonstrated antitumor activity 66 PEGylated interferon beta 1a 66 metastatic kidney 66 SCH # 66 UPLYSO 66 Myelodysplastic Syndrome MDS 66 p# biomarker 66 refractory ovarian cancer 66 RoACTEMRA 66 nitazoxanide 66 locoregional disease 66 androgen independent 66 crizotinib PF # 66 neurologic progression 66 PKC# 66 CD3 monoclonal antibody 66 sorafenib 66 efavirenz EFV 66 nab paclitaxel 66 Gemcitabine 66 acute GvHD 66 ORENCIA ® 66 imatinib resistant 66 bosentan 66 pegylated interferon alpha 2a 66 Gemzar ® 66 Natalizumab 66 argatroban 66 Camptosar ® 66 null responder 66 neoadjuvant therapy 66 olmesartan 66 IMA# 66 boosted protease inhibitor 66 refractory gout 66 5 Fluorouracil 66 complete cytogenetic response 66 virological failure 66 melphalan prednisone 66 docetaxel 66 advanced hepatocellular carcinoma 66 mcg albinterferon alfa 2b 66 chronic ITP patients 66 severe neutropenia 66 HCV SPRINT 66 IRX 2 66 azacytidine 66 colon carcinoma 66 sunitinib Sutent ® 66 Sorafenib 66 non metastatic osteosarcoma 66 methotrexate monotherapy 66 sitaxsentan 66 canakinumab 66 Pegasys ® 66 peg interferon 66 secondary hyperparathyroidism 66 sorafenib Nexavar ® 66 antibody MAb 66 TYKERB 66 trimethoprim sulfamethoxazole 66 dose cytarabine 66 genotype 1a 66 prucalopride 66 Median PFS 66 histone deacetylase HDAC inhibitor 66 CRp 66 Interferon alfa 66 hypereosinophilic syndrome 66 gastric adenocarcinoma 66 alefacept 66 infusional 5-FU/LV 66 Capecitabine 66 adjuvant therapy 66 Gleevec Glivec 66 lapatinib Tykerb 66 stage IIIb 66 Kepivance 66 IFN alfa 66 baseline LDH 66 recurrent metastatic 66 EGFR inhibitors 66 hypomethylating agents 66 oral vancomycin 66 Fibrillex TM 66 octreotide 66 cetuximab Erbitux 66 5FU 66 CCX# B 66 Pralatrexate 66 nucleoside naive 66 Xelox 66 INCB# [001] 66 ZOLINZA 66 achieved sustained virological 66 multicenter randomized placebo controlled 66 octreotide LAR 66 erlotinib Tarceva 66 receptor inhibitor 66 alpha 2a 66 BARACLUDE R 66 paclitaxel Taxol 66 plus COPEGUS 66 Dacogen injection 66 romiplostim 66 Hormone Refractory Prostate Cancer 66 subcutaneously administered 66 certolizumab 66 hepatitis C genotype 66 Ophena TM 66 epithelial tumors 66 fluvastatin 66 BENICAR HCT 66 beta 1a 66 eltrombopag 66 haematologic 66 evaluating T DM1 66 leukemia ALL 66 tipranavir ritonavir 66 hepatocellular carcinoma HCC 66 pegylated interferon alfa 66 Chronic Hepatitis C 66 HBeAg + 66 NATRECOR R 66 ErbB2 positive 66 CMV disease 66 Cethromycin 66 Decitabine 65 systemic ALCL 65 fludarabine 65 peginterferon alfa 65 FOLPI 65 Gliadel Wafer 65 Pazopanib 65 BCG refractory 65 ULORIC 65 gemcitabine cisplatin 65 refractory prostate cancer 65 ancrod 65 trastuzumab Herceptin 65 relapsed CLL 65 Peginterferon Alfa 2a 65 relapsing multiple sclerosis 65 Tipranavir 65 Telbivudine 65 Platinol ® 65 EGFR tyrosine kinase inhibitor 65 Panzem R NCD 65 resistant ovarian cancer 65 TACE 65 undetectable HBV DNA 65 Azacitidine 65 dose cohort 65 peginterferon alfa 2b 65 metastatic castrate resistant 65 basal cell carcinoma BCC 65 dose dexamethasone 65 LHRH receptor positive 65 HBeAg 65 iniparib 65 refractory colorectal cancer 65 malignant ascites 65 Ozarelix 65 Pivotal Phase III 65 hormone refractory metastatic prostate 65 hormone refractory 65 Folfox 65 Relapsing Remitting Multiple Sclerosis 65 Newly Diagnosed Multiple Myeloma 65 PegIFN RBV 65 INCB# [003] 65 iclaprim 65 Gefitinib 65 TKI therapy 65 Tasigna nilotinib 65 erythropoietic 65 Hepsera adefovir dipivoxil 65 ß blockers 65 systemic anaplastic large 65 nicardipine 65 Gleevec imatinib mesylate 65 sargramostim 65 CBLC# 65 splenectomized patients 65 PROSTVAC VF 65 EndoTAG TM -1 65 -#.# log# 65 rilonacept 65 postmenopausal osteoporotic women 65 TMC# C# 65 Tavocept 65 vinca alkaloid 65 tipranavir 65 colorectal cancer liver metastases 65 Multiple Myeloma MM 65 neoadjuvant 65 Virulizin ® 65 tipranavir r 65 peginterferon alfa 2a Pegasys 65 oral prodrug 65 Troxatyl 65 lintuzumab 65 trastuzumab DM1 65 chronic HCV 65 Vandetanib 65 HER2 overexpression 65 AEGR 65 mutated KRAS 65 urothelial carcinoma 65 Acute Myelogenous Leukemia AML 65 celgosivir 65 HoFH 65 Onalta ™ 65 phase IIb trial 65 Neuvenge 65 Vectibix monotherapy 65 Adjuvant chemotherapy 65 Navelbine 65 anthracyclines taxanes 65 Nilotinib 65 COMBIVIR 65 taxane refractory 65 CIMZIA TM certolizumab pegol 65 Betaferon R 65 fulvestrant 65 evaluating picoplatin 65 XL# SAR# 65 Hycamtin ® 65 xanthine oxidase inhibitor 65 HGS ETR2 65 Sutent sunitinib 65 Ranibizumab 65 SHPT 65 doxorubicin HCl liposome injection 65 renal cell carcinoma 65 hepatorenal syndrome 65 bleomycin 65 GnRH agonist 65 rapid virologic response 65 TREANDA 65 fosbretabulin 65 Meets Primary Endpoint 65 dexamethasone Decadron 65 relapsed SCLC 65 Epratuzumab 65 Rituxan rituximab 65 Taxotere R 65 Ranolazine 65 Cloretazine R VNP#M 65 cholangiocarcinoma 65 XYOTAX TM 65 LymphoStat B belimumab 65 luteinizing hormone releasing 65 Halaven 65 MCyR 65 Prostate AdenoCarcinoma Treatment 65 IMPACT IMmunotherapy 65 proteasome inhibitor 65 interferon gamma 1b 65 diagnosed multiple myeloma 65 BCG refractory carcinoma 65 CR# vcMMAE 65 lenalidomide Revlimid R 65 Adalimumab 65 CsA 65 relapsed refractory AML 65 Randomized Phase 65 zalutumumab 65 recurrent malignant glioma 65 calcineurin inhibitor 65 CCyR 65 Ambrisentan 65 hypercalcemia 65 entecavir 65 refractory cutaneous T 65 mg kg dose 65 generation purine nucleoside 65 non splenectomized 65 ketolide antibiotic 65 resistant hormone refractory 65 4mg/kg 65 antithrombotic 65 esophageal candidiasis 65 non squamous 65 IMiDs ® compound 65 ganetespib 65 mitoxantrone 65 Monotherapy 65 adjuvant radiotherapy 65 atrial fibrillation budiodarone ATI 65 curative resection 65 NATRECOR ® 65 bosutinib 65 EGFR mutation positive 65 Phase IIIb clinical 65 acetonide FA 65 cytoreduction 65 nucleoside analogue 65 Dalbavancin 65 fluorouracil 65 Clevudine 65 cisplatin vinorelbine 65 IMGN# 65 antiretroviral naïve 65 Ceplene/IL-2 65 PRT# 65 polycythemia vera essential thrombocythemia 65 PROVENGE sipuleucel T 65 Lubiprostone 65 rFVIIa 65 Targretin capsules 65 Targretin 65 oral rivaroxaban 65 chemotherapeutic regimen 65 Retreatment 65 Increlex R 65 Jevtana 65 pegaptanib 65 APTIVUS R 65 flutamide 65 ritonavir boosted lopinavir 65 follicular lymphoma 65 RSR# 65 rALLy 65 lymphadenectomy 65 BEXXAR Therapeutic Regimen 65 anticancer therapy 65 Glioblastoma Multiforme 65 NovoTTF 65 achieved sustained virologic 65 cinacalcet 65 Virologic 65 anti angiogenic agents 65 Herceptin trastuzumab 65 enfuvirtide 65 gastrointestinal stromal tumors 65 plasma kallikrein inhibitor 65 LHRH analogues 65 adefovir 65 levosimendan 65 macroalbuminuria 65 Free Survival PFS 65 anagrelide 65 GAMMAGARD 65 vinca alkaloids 65 REVLIMID ® 65 thymalfasin 65 Phase Ib study 65 APPRAISE 65 mcg dose 65 PREZISTA rtv 65 virological response 65 OvaRex ® MAb 65 dopamine partial agonist 64 partial remissions 64 hematopoietic cancers 64 tumor necrosis 64 receiving prophylactic anticoagulation 64 induced macular edema 64 autoantibody positive 64 Surgical resection 64 LHRH agonist 64 Brentuximab Vedotin SGN 64 IFN beta 64 myelodysplastic syndrome MDS 64 bortezomib Velcade R 64 diarrhea predominant irritable 64 advanced metastatic renal 64 de novo kidney transplant 64 naïve HCV 64 essential thrombocythemia ET 64 miconazole Lauriad ® 64 etanercept Enbrel 64 R lenalidomide 64 androgen deprivation 64 IL# PE#QQR 64 imipenem 64 HER2 positive 64 lintuzumab SGN 64 immunotherapeutic agent 64 HGS ETR1 64 Advagraf 64 topotecan 64 idraparinux 64 NOXAFIL 64 TBC# 64 familial amyloidotic polyneuropathy FAP 64 STRIDE PD 64 T#I mutation 64 AA Amyloidosis 64 ABVD 64 Ixempra 64 interferon α 64 desvenlafaxine succinate 64 PROMACTA 64 CCR5 antagonist 64 β blockers 64 Kinoid 64 Diffuse Large B 64 pazopanib 64 visilizumab 64 Allovectin 7 64 metastatic bladder 64 aflibercept VEGF Trap 64 febrile neutropenia 64 nephrotoxicity 64 IV metastatic melanoma 64 Ecallantide 64 ertapenem 64 efalizumab 64 stable angina pectoris 64 mg/m2 dose 64 DMARD therapy 64 Cloretazine R 64 capecitabine Xeloda 64 pT3 64 seliciclib 64 Platinol 64 HER2 + 64 hepatic metastases 64 verteporfin 64 custirsen 64 valopicitabine 64 PAOD 64 infusional 64 XIENCE V PROMUS Stent 64 Annamycin 64 BRIM3 64 piperacillin tazobactam 64 neratinib 64 antiangiogenic agent 64 stavudine d4T 64 EGFR expressing 64 antimetabolite 64 multicentre randomized 64 pCR 64 FOLFOX regimen 64 YERVOY 64 metastatic androgen independent 64 pancreatic neuroendocrine tumors 64 thrombocytopenic 64 TELINTRA 64 plus ribavirin 64 oral clodronate 64 candidemia 64 antithymocyte globulin 64 IgG1 monoclonal antibody 64 pediatric acute lymphoblastic 64 Pfizer Sutent 64 epithelial ovarian cancer 64 Boceprevir 64 peritoneal carcinomatosis 64 hepatitis C HCV 64 dalteparin 64 CIN2 + 64 COPAXONE ® 64 SNT MC# 64 paclitaxel Taxol R 64 nucleotide analogue 64 Apoptone 64 investigational monoclonal antibody 64 tafamidis 64 phase IIa clinical 64 antitumor effect 64 SinuNase TM 64 Omacetaxine 64 Rituximab 64 opioid induced constipation OIC 64 Hodgkin lymphoma HL 64 5 FU leucovorin 64 pT2 64 humanised monoclonal antibody 64 Cyclosporine 64 Methylnaltrexone 64 tyrosine kinase inhibitors TKIs 64 mitoxantrone plus 64 anti leukemic 64 eosinophilic asthma 64 plasma uric acid 64 evaluable 64 doxorubicin cyclophosphamide 64 CD# antibody [001] 64 antithrombotics 64 HSCT 64 pralatrexate 64 titrated glipizide 64 surrogate endpoint 64 ZYVOX 64 Enzastaurin 64 adjuvant tamoxifen 64 chronic HCV infection 64 taxotere 64 vemurafenib 64 MKC# MT 64 cutaneous T 64 Taxotere chemotherapy 64 dose cohorts 64 lenalidomide dexamethasone 64 Quinamed 64 lymphoid malignancies 64 icatibant 64 sustained virologic response 64 Certolizumab pegol 64 novel histone deacetylase 64 Adjuvant Treatment 64 K ras mutations 64 nilotinib Tasigna ® 64 EOquin TM 64 tyrosine kinase inhibitors 64 Faslodex 64 Femara letrozole 64 Vicriviroc 64 palifermin 64 CAELYX 64 CR CRu 64 Chronic Lymphocytic Leukemia 64 OHR/AVR# 64 intravesical instillation 64 achieved PASI 64 pemetrexed 64 H. pylori eradication 64 NSABP B 64 evaluable patients 64 paclitaxel cisplatin 64 HuLuc# 64 mg QD 64 Everolimus 64 Zolinza 64 refractory metastatic 64 remission CR 64 previously untreated follicular 64 ximelagatran 64 Tamibarotene 64 paclitaxel poliglumex 64 R sorafenib tablets 64 Zarnestra 64 6 mercaptopurine 64 #mg QD [001] 64 dose escalation clinical 64 EOquin 64 bladder carcinoma 64 INTELENCE 64 cutaneous melanoma 64 Lenocta 64 Hazard Ratio 64 cytogenetic response 64 investigational antiplatelet agent 64 colorectal carcinoma 64 novel VDA molecule 64 eribulin mesylate 64 mTOR inhibitors 64 apremilast 64 Rebif ® 64 paclitaxel Taxol ® 64 nosocomial pneumonia 64 resected pancreatic cancer 64 Dacogen decitabine 64 ZD# [001] 64 HCV genotype 1 64 preoperative chemotherapy 64 irinotecan containing 64 Bosutinib 64 achieve sustained virologic 64 endocrine therapies 64 NRTI 64 FluCAM 64 vicriviroc 64 fosamprenavir 64 LMWH 64 bortezomib Velcade 64 PROSTVAC TM 64 Pertuzumab 64 cutaneous T cell 64 PNP inhibitor 64 tirofiban 64 CML CP 64 hepatotoxicity 64 Capesaris 64 APTIVUS ritonavir 64 SCIg 64 PSMA ADC 64 Ziprasidone 64 FOLOTYN 64 Actimmune ® 64 refractory CLL 64 GHRH 64 Erbitux cetuximab 64 TAXOTERE R 64 evaluable subjects